Using Dose Titration to Resolve Nausea on Wegovy (semaglutide 2.4 mg)

How much do nausea rates differ by dose?

Nausea is more common on Wegovy than on placebo. In pooled adult trials of the 2.4 mg injection, nausea was reported by 44% of adults versus 16% on placebo [1]. In two 72-week trials that compared doses directly in adults with obesity, nausea was reported by 39% of those on semaglutide 7.2 mg, 35% on 2.4 mg and 13% on placebo; vomiting by 22%, 16% and 6% [1]. Rates from separate trials are not directly comparable.

Semaglutide is a GLP-1 receptor agonist that delays gastric emptying and activates GLP-1 receptors in brain areas that regulate appetite and calorie intake [1]. Wegovy starts everyone at 0.25 mg and climbs in four-week blocks rather than opening at the maintenance dose [1].

Nausea is the adverse reaction most often leading to discontinuation. Across three pooled placebo-controlled trials of 2.4 mg in 2,116 adults, any gastrointestinal reaction occurred in 73% vs 47% on placebo, and 6.8% vs 3.2% stopped treatment for an adverse reaction, with nausea the leading cause (1.8% vs 0.2%) [1].

What exactly does the Wegovy label schedule?

The injection is once weekly, on the same day each week, at any time of day, with or without meals, into the abdomen, thigh or upper arm [1]. The escalation table runs 0.25 mg for weeks 1-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12, 1.7 mg for weeks 13-16, then maintenance from week 17 [1].

Maintenance for weight reduction in adults is 2.4 mg, with 1.7 mg listed as an alternative; adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go up to a maximum of 7.2 mg weekly [1]. For cardiovascular risk reduction the maintenance dose is 2.4 mg or 1.7 mg, and for MASH it is 2.4 mg, which may be reduced to 1.7 mg [1]. Children 12 and older top out at 2.4 mg [1].

Can you simply hold each step longer than 4 weeks?

The labeled table raises the dose every 4 weeks, and STEP 1, the 68-week trial of 1,961 adults, used 16 weeks of dose escalation to reach 2.4 mg [1][2]. An April 2024 version of the label says to follow the escalation schedule to minimize gastrointestinal adverse reactions, and that if patients do not tolerate a dose during escalation, consider delaying escalation for 4 weeks [5]. Across three pooled trials of Wegovy 2.4 mg injection, 6.8% stopped treatment because of an adverse reaction, including 1.8% who stopped because of nausea [1].

Is going back down a labeled option?

Yes, at one specific level. The Wegovy label lists 1.7 mg as a maintenance dose for weight reduction and for cardiovascular risk reduction in adults, with 2.4 mg described as the recommended dose, and allows MASH treatment to be reduced from 2.4 mg to 1.7 mg [1]. The 0.25 mg, 0.5 mg and 1 mg doses appear in the escalation table rather than the maintenance list [1].

What happens after a missed dose or a gap?

The label's rule is that a missed weekly dose should be given if the next scheduled dose is more than 2 days away; if it is closer than that, the missed dose is skipped [1]. The label describes re-escalation from a lower dose after 2 or more consecutive missed doses [1].

Semaglutide has an elimination half-life of about one week, and the drug remains in the body for roughly 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection or 25 mg tablet [1].

What about doses below 0.25 mg?

0.25 mg is the labeled starting dose [1]. Drugs@FDA lists Wegovy injection in fixed strengths of 0.25, 0.5, 1, 1.7 and 2.4 mg, a FlexTouch 9.6 mg/3 mL presentation and a 7.2 mg strength (Wegovy HD) [3]. Anything below 0.25 mg falls outside the labeled schedule.

Compounded semaglutide is a separate product. FDA reports dosing errors with compounded injectable semaglutide, including patients measuring the wrong amount and doses above the labeled dose, and says compounded drugs are not FDA approved or reviewed for safety, effectiveness or quality before marketing [4]. As of 2026-05-31 the agency had received 990 adverse event reports for compounded semaglutide and says the true number is likely higher [4].

What the label flags besides titration

The Wegovy label advises watching for acute pancreatitis, which may cause persistent severe abdominal pain sometimes radiating to the back, with or without nausea or vomiting, and states that Wegovy should be discontinued if pancreatitis is suspected [1]. It also warns about acute kidney injury from volume depletion, which occurred in 0.4 vs 0.2 cases per 100 patient-years (7 vs 4 adults), more often in people with prior kidney impairment and during dose titration, often after gastrointestinal fluid loss; the label advises monitoring kidney function in patients reporting reactions that could cause volume depletion [1].

Severe gastrointestinal reactions were reported by 4.1% of people on Wegovy 2.4 mg vs 0.9% on placebo [1].